From Mind To Market - Boehringer Ingelheim

22
We have the track record
Many organizations have achieved success by
partnering with Boehringer Ingelheim. The list
ranges from small research-based operations to
large multinational pharmaceutical companies.
Our most well-known biotechnology alliance is
perhaps with Genentech, Inc., San Francisco,
with which we have worked closely since 1983.
Together we developed the recombinant DNAderived
tissue plasminogen activator (rt-PA),
a thrombolytic agent used in the treatment of
myocardial infarction, pulmonary embolism and
stroke. rt-PA was marketed in North America
by Genentech as activase®, and by Boehringer
Ingelheim in over 50 countries under the trade
name actilyse®. It is the most successful biopharmaceutical
manufactured and marketed by
Boehringer Ingelheim. The two companies have
worked together on the next generation of tissue
plasminogen activator which as TNKase® in the
USA, and as metalyse® in Europe has helped
an increasing number of AMI (Acute Myocardial
Infarction) and stroke patients since 2001.
Other products jointly developed in collaboration
with Genentech are imukin® (interferon gamma),
which is approved for chronic granulomatosis,
and tumor necrosis factor (TNF) alpha, for the
treatment of soft tissue sarcoma, under the
brand name beromun®.
In order to maintain and improve our competitive
edge in a constantly evolving field, we maintain
strong links with a number of universities
and industrial partners in the area of new technologies,
such as expression systems, optimized
host cells, media and process optimization,
expanded bed absorption, affinity chromatography,
virus inactivation, on-line analysis, refolding
and new application forms.
Own biopharmaceuticals brought to market:
Generic name Brand name Therapeutic area
Tissue plasminogen actilyse® Myocardial infarction,
activator (rt-PA) pulmonary embolism,
stroke
Second generation metalyse® Myocardial infarction
tissue plasminogen
activator (TNK-tPA)
Interferon gamma imukin® Chronic granulomatosis
Tumor necrosis beromun® Soft tissue sarcoma
factor alpha
For customers Boehringer Ingelheim so far introduced
9 DNA-derived biopharmaceutical products
to the market.